We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Noscapine Slows Growth and Spread of Prostate Cancer

By LabMedica International staff writers
Posted on 31 Mar 2010
Noscapine, a nonaddictive derivative of opium commonly used as an additive in cough medicines, has been shown to be effective in limiting the growth and spread of prostate cancer.

A cooperative effort united investigators from the Prostate Cancer Research and Education Foundation (PCREF; San Diego, CA, USA), the University of California, San Diego (UCSD; USA), and the MedInsight Research Institute (Baltimore, MD, USA). More...
They worked with a model comprising nude mice that were injected with human prostate cancer cells.

In the study, the mice received oral noscapine or diluent (control) for 56 days, beginning seven days after inoculation with PC3 human prostate cancer cells; or noscapine for 70 days, beginning seven days before inoculation with the cancer cells.

Findings were published in the February 2010 issue of the journal Anticancer Research. They showed that pretreating the mice with noscapine before injecting them with prostate cancer cells resulted in the tumor growth rate being two-thirds smaller in the noscapine group. Furthermore, lung metastasis rates were 80% less in the mice pretreated with noscapine, and the noscapine group suffered no cancer-related weight loss – compared with significant weight loss in the non-noscapine group. Overall, pretreatment with noscapine gave anticancer benefits similar to those seen for treatment that was given after injection of cancer cells. In both cases, there were no signs of toxicity to normal cells or tissues.

"Based on our research so far, we believe that noscapine could be a very promising treatment to prevent recurrence in such cases due to its excellent safety record and oral bioavailability,” said first author Dr. Israel Barken, medical director of the PCREF. "PCREF is now seeking sponsorship for clinical data collection in postsurgery patients who are at high-risk of recurrence for their prostate cancer.”

Senior author Dr. Moshe Rogosnitzky, director of research at the MedInsight Research Institute, said, "It is MedInsight's belief that many effective treatments for this and other diseases can be selected from the vast armory of existing off-patent and unpromoted drugs. The results of this study, once confirmed in a clinical trial, are an example where we may yet again have an agent that not only has an envious safety record, but is already available for use today.”

Related Links:
Prostate Cancer Research and Education Foundation
University of California, San Diego
MedInsight Research Institute



Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
Pan-Cancer Panel
TruSight Oncology 500
New
Automatic Hematology Analyzer
LABAS F9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.